Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational
- PMID: 32920511
- PMCID: PMC7451059
- DOI: 10.1016/j.biopha.2020.110694
Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational
Abstract
As a process entailing a high turnover of the host cell molecules, viral replication is required for a successful viral infection and requests virus capacity to acquire the macromolecules required for its propagation. To this end, viruses have adopted several strategies to harness cellular metabolism in accordance with their specific demands. Most viruses upregulate specific cellular anabolic pathways and are largely dependent on such alterations. RNA viruses, for example, upregulate both glycolysisand glycogenolysis providing TCA cycle intermediates essential for anabolic lipogenesis. Also, these infections usually induce the PPP, leading to increased nucleotide levels supporting viral replication. SARS-CoV-2 (the cause of COVID-19)that has so far spread from China throughout the world is also an RNA virus. Owing to the more metabolic plasticity of uninfected cells, a promising approach for specific antiviral therapy, which has drawn a lot of attention in the recent years, would be the targeting of metabolic changes induced by viruses. In the current review, we first summarize some of virus-induced metabolic adaptations and then based on these information as well as SARS-CoV-2 pathogenesis, propose a potential therapeutic modality for this calamitous world-spreading virus with the hope of employing this strategy for near-future clinical application.
Keywords: Cellular metabolism; Glycolysis; PPP; SARS-CoV-2; TCA cycle.
Copyright © 2020. Published by Elsevier Masson SAS.
Conflict of interest statement
The authors report no declarations of interest.
Figures





Similar articles
-
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).Viruses. 2020 Jun 10;12(6):628. doi: 10.3390/v12060628. Viruses. 2020. PMID: 32532085 Free PMC article.
-
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature. 2020 Jul;583(7816):469-472. doi: 10.1038/s41586-020-2332-7. Epub 2020 May 14. Nature. 2020. PMID: 32408336 Free PMC article.
-
SARS-CoV-2 RNA polymerase as target for antiviral therapy.J Transl Med. 2020 May 5;18(1):185. doi: 10.1186/s12967-020-02355-3. J Transl Med. 2020. PMID: 32370758 Free PMC article.
-
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24. Biomed Pharmacother. 2020. PMID: 32861965 Free PMC article. Review.
-
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317-325. doi: 10.1093/ehjcvp/pvaa053. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 32464637 Free PMC article. Review.
Cited by
-
The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses.Molecules. 2022 Sep 12;27(18):5928. doi: 10.3390/molecules27185928. Molecules. 2022. PMID: 36144664 Free PMC article. Review.
-
Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients.Sci Rep. 2022 Jun 9;12(1):9510. doi: 10.1038/s41598-022-12751-y. Sci Rep. 2022. PMID: 35680931 Free PMC article.
-
The Triangle Relationship Between Long Noncoding RNA, RIG-I-like Receptor Signaling Pathway, and Glycolysis.Front Microbiol. 2021 Nov 30;12:807737. doi: 10.3389/fmicb.2021.807737. eCollection 2021. Front Microbiol. 2021. PMID: 34917069 Free PMC article. Review.
-
Alpha and gamma mangostins inhibit wild-type B SARS-CoV-2 more effectively than the SARS-CoV-2 variants and the major target is unlikely the 3C-like protease.Heliyon. 2024 May 27;10(11):e31987. doi: 10.1016/j.heliyon.2024.e31987. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38867992 Free PMC article.
-
Molecular docking, pharmacological profiling, and MD simulations of glycolytic inhibitors targeting novel SARS CoV-2 main protease and spike protein.In Silico Pharmacol. 2025 Mar 14;13(1):44. doi: 10.1007/s40203-025-00336-2. eCollection 2025. In Silico Pharmacol. 2025. PMID: 40093584
References
-
- World Health Organization. Situation updates on 12 August, 2020. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019 2020 (Accessed 12 August 2020).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous